Human Reproduction Update Advance Access originally published online on March 31, 2006
Human Reproduction Update 2006 12(3):327-328; doi:10.1093/humupd/dml007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2006. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
Letter to the Editor |
Agonist trigger in the context of OHSS prevention: primum non nocere
Department of Obstetrics and Gynaecology, IVF unit, Rambam Medical Center, PO Box 9602, Haifa 31096, Israel
E-mail: skol@rambam.health.gov.il
| The first 10% of the full text of this article appears below. |
Sir,
Ovarian hyperstimulation syndrome (OHSS) is a pure iatrogenic complication of assisted reproduction technique (ART), affecting young healthy women seeking fertility. According to a WHO report (Hugues, 2001
) this syndrome is responsible to 1 death for every 50 000 treatment cycles, whereas the incidence of severe OHSS is 1%. I assume we all agree that we must thrive to ensure patient safety first, clinical outcome (pregnancy) later. Consequently, a reliable means for OHSS prevention is badly needed.
GnRH